{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:09:47Z","timestamp":1792454987811,"version":"4.5.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2017,9,29]]},"DOI":"10.3233\/jhd-170262","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T11:17:51Z","timestamp":1506683871000},"page":"255-263","source":"Crossref","is-referenced-by-count":38,"title":["Clinical Trials Corner: September 2017"],"prefix":"10.1177","volume":"6","author":[{"given":"Filipe B.","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Huntington\u2019s Disease Centre, University College London, London, UK"},{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-170262_ref1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/1745-6215-15-428","article-title":"Characteristics of clinical trial websites: Information distribution between ClinicalTrials.gov and 13 primary registries in the WHO registry network","volume":"15","author":"Ogino","year":"2014","journal-title":"Trials"},{"issue":"9","key":"10.3233\/JHD-170262_ref2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database\u2013update and key issues","volume":"364","author":"Zarin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.3233\/JHD-170262_ref3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13063-016-1310-8","article-title":"When are clinical trials registered? An analysis of prospective versus retrospective registration","volume":"17","author":"Harriman","year":"2016","journal-title":"Trials"},{"key":"10.3233\/JHD-170262_ref4","volume-title":"CHDI12th Annual HD Therapeutics Conference","author":"Rodrigues","year":"2017"},{"issue":"3","key":"10.3233\/JHD-170262_ref5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-170262_ref6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"key":"10.3233\/JHD-170262_ref7","volume-title":"CHDI 12th Annual HD Therapeutics Conference","author":"Rodrigues","year":"2017"},{"issue":"2","key":"10.3233\/JHD-170262_ref8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JHD-170245","article-title":"Fifteen years of clinical trials in Huntington\u2019s disease: A very low clinical drug development success rate","volume":"6","author":"Travessa","year":"2017","journal-title":"J Huntingtons Dis"},{"issue":"1-2","key":"10.3233\/JHD-170262_ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2004.02.016","article-title":"Laquinimod (ABR-62) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1\/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats","volume":"156","author":"Yang","year":"2004","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.3233\/JHD-170262_ref13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019sdisease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"issue":"6","key":"10.3233\/JHD-170262_ref16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal gangliafunction in Huntington\u2019s disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"key":"10.3233\/JHD-170262_ref20","doi-asserted-by":"crossref","unstructured":"Seeman P , Tokita K , Matsumoto M , Matsuo A , Sasamata M , Miyata K . The dopaminergic stabilizer ASP\/ACR16 selectively interacts with D2(High) receptors 2009;63(10):930\u20134.","DOI":"10.1002\/syn.20663"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-170262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:20Z","timestamp":1777453040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-170262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":12,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jhd-170262","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]}}}